

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8671

Robert Yongxin ZHAO

153(b) Divisional Appln. of
Appln. No. 10/116,053

Confirmation No.: 3809 (parent)

Group Art Unit: 1626 (parent)

Filed: October 27, 2003

Examiner: R. Shiao (parent)

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 and 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which are all the references of record in parent application No. 10/116,053. Applicant is not submitting duplicate copies of these references but requests that they be listed on the face of any patent granted on the above application. (See 37 CFR §1.98(d)). Copies of any cited copending applications, if not previously submitted, are being submitted herewith.

Information Disclosure Statement
1.53(b) Divisional Application of
U.S. Serial No. 10/116,053

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

PREVIOUS NO
#44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date:

OCT 27 2003

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/116,053 (parent)
				Confirmation Number	3809 (parent)
				Filing Date	OCT 27 2003
				First Named Inventor	Robert Youngxin ZHAO
				Art Unit	1626 (parent)
Examiner Name	Rei Tsang Shiao (parent)				
Sheet	1	of	1	Attorney Docket Number	A8671

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 5,475,092		12/12/95	Ravi V.J. Chari, et al.
		US 5,585,499		12/17/96	Ravi V.J. Chari, et al.
		US 5,846,545		12/08/98	Ravi V.J. Chari, et al.
		US 6,534,660	B1	03/18/03	Ravi V.J. Chari, et al.
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ <i>(if known)</i>			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		KATSUSHIGE GOMI, et al., "Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotics," Jpn. J. Cancer Research, January 1992, pages 113-120, Vol. 83.	
		CHONG-SOON LEE, et al., "Determination of the Structural Features of (+) -CC-1065 That Are Responsible for Bending and Winding of DNA," Chem. Res. Toxicol., 1991, pages 203-213, Vol. 4, No. 2.	
		DAVID H. SWENSON, et al., "Evaluation of DNA Binding Characteristics of Some CC-1065 Analogs," Chem.-Biol. Interactions, 1988, pages 199-213, Vol. 67.	
		LI H. LI, et al., "Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065," Investigational New Drugs, 1991, pages 137-148, Vol. 9, No. 2.	
		BRUCE W. ENNIS, et al., "The EGF Receptor System as a Target for Antitumor Therapy," Cancer Investigation, 1991, pages 553-562, Vol. 9, No. 5.	
		MAGDA C. GUTOWSKI, et al., "Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates," Cancer Res. 1991, pages 5471-5475, Vol. 51, No. 20.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/116,053 (parent)
				Confirmation Number	3809 (parent)
				Filing Date	October 27, 2003
				First Named Inventor	Robert Yongxin ZHAO
				Art Unit	1626 (parent)
				Examiner Name	Rei Tsang Shiao (parent)
Sheet	2	of	2	Attorney Docket Number	A8671

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,060,608	A	07/09/00	Dale L. Boger
		US 6,548,530	B1	04/15/03	Dale L. Boger
		US 5,475,092	A	12/12/95	Dale L. Boger
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		DALE L. BOGER, et al., "Parallel Synthesis and Evaluation of 132 (+)-1, 2, 9, 9aTetrahydrocyclopropa[c] benz [e] indol -4 -one (CBI Analogues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Doman," Journal of Organic Chemistry, 2001, 66(20), 6654-6661. (abstract)	
		YUQIANG WANG, "Synthesis and Preliminary Biological Evaluations of CC-1065 Analogues: Effects of Different Linkers and Terminal Amides on Biological Activity," Journal of Medicinal Chemistry (2000), 43(8), 1541-1549.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.